Neuroprotective Role of
Sovateltide in Ischemic Stroke: A Review of Preclinical and Clinical Evidence
Abishek S1*, S.Lavanya2, Balakrishnan R3
1.
M.Pharm, Department of Pharmacy
Practice, PSG College of Pharmacy,Coimbatore
2.
Professor, Department of Pharmacy Practice, PSG College of
Pharmacy, Coimbatore
3.
Head and Department of
Neurology, PSG Hospital, Coimbatore
*Correspondence: abisheksaravanan3@gmail.com
DOI: https://doi.org/10.71431/IJRPAS.2025.4608
|
Article
Information
|
|
Abstract
|
|
Review Article
Received: 23/06/2025
Accepted: 27/06/2025
Published: 30/06/2025
Keywords
Ischemic
stroke; Sovateltide; Neuroprotection; Endothelin B receptor; Angiogenesis.
|
|
There are few
treatment options for ischemic stroke, which mostly focuses on reperfusion,
and it continues to be a leading cause of mortality and permanent disability
globally. Neuroprotective medicines are desperately needed in order to
improve functional recovery and encourage brain restoration. The capacity of
sovateltide, a novel selective endothelin B (ETB) receptor agonist, to
promote neurogenesis, angiogenesis, and decrease neuronal death has made it a
viable candidate. This review synthesizes current
preclinical and clinical evidence regarding the efficacy and safety of
sovateltide in ischemic stroke management. Preclinical studies in rodent
models demonstrated significant reductions in infarct size, improved motor
function, increased expression of neurotrophic factors, and enhanced neural
stem cell proliferation. According
to clinical data from Phase II and III randomized controlled trials, patients
receiving sovateltide had noticeably better functional outcomes than those
receiving standard care alone, as indicated by the modified Rankin Scale
(mRS), National Institutes of Health Stroke Scale (NIHSS), and Barthel Index.
Importantly, no major adverse effects were reported, supporting its
favorable safety profile. These findings indicate that sovateltide offers
neuroprotective benefits beyond current reperfusion therapies. Future
large-scale trials and long-term follow-up studies are warranted to confirm
its therapeutic potential and optimize its clinical use in ischemic stroke
treatment.
|
INTRODUCTION
Burden of Ischemic Stroke and Need for Neuroprotective Agents
Ischemic stroke occurs due to an
arterial occlusion in the brain, leading to irreversible neuronal damage,
functional impairment, and significant socioeconomic burden. Current therapeutic
approaches include intravenous thrombolysis (IV tPA) and mechanical
thrombectomy, but these treatments have limitations, including a narrow
therapeutic window and risk of hemorrhagic complications. Despite advances in
acute stroke care, no FDA-approved neuroprotective agents exist to mitigate
ischemic damage. Neuroprotective drugs aim to preserve brain tissue beyond the
ischemic core, improve functional recovery, and enhance long-term outcomes.
Sovateltide, a selective ETB receptor agonist, has shown promise in preclinical
and early clinical studies by promoting neurovascular repair and reducing
apoptosis[1-4].
Pharmacological Mechanism of Sovateltide
Sovateltide exerts its effects by
selectively activating endothelin B receptors (ETB), which play a vital role in
neurovascular regulation. The key mechanisms include:
n Neurogenesis:
Promotes neural
stem/progenitor cells' (NSPCs') migration, differentiation, and proliferation,
which aids in brain repair.
n Angiogenesis:
Makes cerebral
perfusion by encouraging the growth of new blood vessels and endothelial cells.
n Anti-apoptotic
Effects: Reduces ischemia-induced apoptosis by
upregulating anti-apoptotic proteins (e.g., Bcl-2) and downregulating
pro-apoptotic factors (e.g., Bax, caspase-3).
n Inflammation
Modulation: Inhibits excessive neuroinflammation
by suppressing pro-inflammatory cytokines (TNF-α, IL-6) and promoting
microglial homeostasis.
n Oxidative
Stress Reduction: Decreases reactive oxygen species
(ROS) levels, preventing secondary neuronal injury[5,6].
PRECLINICAL EVIDENCE
Animal Models of Ischemic Stroke
Multiple studies utilizing middle
cerebral artery occlusion (MCAO) models in rodents have demonstrated
significant improvements in functional recovery and infarct volume reduction
with sovateltide administration.
Key Preclinical Findings
l Rats
treated with sovateltide showed a 50% reduction in infarct size compared to
controls.
l Motor
function, assessed via the Rotarod test, significantly improved within 7-14
days post-stroke.
l Neurotrophic factors, including nerve growth
factor (NGF), vascular endothelial growth factor (VEGF), and brain-derived
neurotrophic factor (BDNF), were shown to be upregulated.
l Increased neuronal survival was found in the
subventricular zone (SVZ) and peri-infarct cortex, according to histological
examination.
Cellular and Molecular Studies
In
vitro studies have confirmed that sovateltide:
l Increases
neural stem cell differentiation into mature neurons and astrocytes.
l Enhances
astrocyte-mediated neuroprotection via ETB receptor activation.
l Reduces
oxidative stress markers such as malondialdehyde (MDA) and increases
antioxidant enzyme levels like superoxide dismutase (SOD)[6,7].
CLINICAL EVIDENCE
Phase I, II and III Clinical Trials
Preliminary clinical studies have
evaluated the efficacy, safety, and pharmacokinetics of sovateltide in stroke
patients.
Phase I (Safety & Tolerability)
l Conducted
in healthy volunteers, demonstrating no serious adverse effects at various dose
levels.
Phase II (Efficacy in Stroke Patients)
A randomized, placebo-controlled
trial involving 40 ischemic stroke patients evaluated the impact of sovateltide
on functional recovery.
Primary outcomes:
ü At day 90, there was a notable improvement in
the modified Rankin Scale (mRS) ratings.
ü National Institutes of Health Stroke Scale
(NIHSS) ratings recovered more quickly than those in the placebo group.[8].
Secondary outcomes:
ü Cerebral
perfusion scans indicated improved blood flow in affected brain regions.
ü
No major hemorrhagic or
thrombotic complications observed.
Figure 1:
Phase II clinical trial
Phase III clinical trial
A
multicenter, randomised, double-blind, placebo-controlled Phase III clinical
trial of sovateltide was conducted in India for patients with cerebral ischemic
stroke who were receiving standard of care (SOC).
Primary Outcomes:
ü At 90 days
post-treatment, 76.1% of patients receiving sovateltide demonstrated an
improvement of ≥2 points on the mRS, compared to 52.9% in the control group
(p=0.005). Furthermore, 80.6% of sovateltide-treated patients achieved an mRS
score of 0-2, indicating better functional outcomes, versus 55.7% in the
control group (p=0.002).
ü The sovateltide group's mean NIHSS score at 90
days was considerably lower (1.98) than that of the control group (3.57)
(p=0.002), indicating improved neurological status.
ü Patients
treated with sovateltide had a mean Barthel Index score of 86.0 at 90 days,
higher than the control group's 75.9 (p=0.011), indicating better performance
in daily living activities.
Secondary Outcomes:
ü The
sovateltide group had a mean score of 87.0 on the EuroQol scale at 90 days,
compared to 80.0 in the control group (p=0.055), suggesting an enhancement in
quality of life, though this difference was not statistically significant.
ü
The mean SSQOL score was 4.17 in
the sovateltide group and 3.91 in the control group at 90 days (p=0.67),
indicating a non-significant trend toward better stroke-specific quality of
life in the treatment group[9].
Figure 2:
Phase III clinical trial
Comparative Studies with Standard Therapy
A
study comparing sovateltide + standard therapy (antiplatelets, tPA) vs.
standard therapy alone found:
l A
30% greater improvement in mRS scores at 3 months in the combination therapy
group.
l Higher
rates of functional independence (mRS ≤2) at follow-up[10].
CHALLENGES AND FUTURE DIRECTIONS
While sovateltide shows strong
preclinical and early clinical promise, several challenges remain:
l Studies
needed to determine the best regimen for long-term neuroprotection.
l Current
trials focus on 3-month recovery, but long-term follow-ups are needed to assess
sustained neuroprotection.
l Potential
synergistic effects with thrombolytics, neurorehabilitation programs, and
regenerative therapies (stem cells, exosomes) need further exploration[11,12].
CONCLUSION
Sovateltide represents a promising
neuroprotective strategy in the ischemic stroke management, with both
preclinical and emerging clinical evidence supporting its role in promoting
neurogenesis, angiogenesis, and overall functional recovery. Its unique mechanism of action as an
endothelin-B receptor agonist enhances the effectiveness of current reperfusion
treatments including mechanical thrombectomy and thrombolysis.
The preliminary results suggest that Sovateltide may accelerate neurological
recovery, reduce infarct size, and enhance long-term outcomes in stroke
patients. Moreover, its favorable safety profile further enhances its potential
as an adjunctive therapy. However, to validate these findings and assess its
efficacy across diverse patient groups, large-scale, multicenter randomized
controlled trials are essential. If proven effective, Sovateltide could become
an integral part of standard stroke management, addressing the current unmet
need for neuroprotective agents in acute ischemic stroke care.
REFERENCES
1.
Mergenthaler P, Dirnagl U, Kunz A. Ischemic stroke: basic
pathophysiology and clinical implication. InNeuroscience in the 21st century:
From basic to clinical 2022 Oct 18 (pp. 3807-3827). Cham: Springer
International Publishing.
2. Tsivgoulis G,
Katsanos AH, Sandset EC, Turc G, Nguyen TN, Bivard A, Fischer U, Khatri P.
Thrombolysis for acute ischaemic stroke: current status and future
perspectives. The Lancet Neurology. 2023 May 1;22(5):418-29.
3. Fisher M, Savitz
SI. Pharmacological brain cytoprotection in acute ischaemic stroke—renewed hope
in the reperfusion era. Nature Reviews Neurology. 2022 Apr;18(4):193-202.
4. Ranjan AK,
Briyal S, Khandekar D, Gulati A. Sovateltide (IRL-1620) affects neuronal
progenitors and prevents cerebral tissue damage after ischemic stroke. Canadian
Journal of Physiology and Pharmacology. 2020;98(9):659-66.
5. Ranjan AK,
Briyal S, Gulati A. Sovateltide (IRL-1620) activates neuronal differentiation
and prevents mitochondrial dysfunction in adult mammalian brains following
stroke. Scientific reports. 2020 Jul 29;10(1):12737.
6. Mavridis T,
Mavridi A, Karampela E, Galanos A, Gkiokas G, Iacovidou N, Xanthos T.
Sovateltide (ILR-1620) Improves Motor Function and Reduces Hyperalgesia in a
Rat Model of Spinal Cord Injury. Neurocritical Care. 2024 Oct;41(2):455-68.
7. Ramos MD, Briyal
S, Prazad P, Gulati A. Neuroprotective effect of sovateltide (IRL 1620, PMZ
1620) in a neonatal rat model of hypoxic-ischemic encephalopathy. Neuroscience.
2022 Jan 1;480:194-202.
8. Gulati A,
Agrawal N, Vibha D, Misra UK, Paul B, Jain D, Pandian J, Borgohain R. Safety
and efficacy of sovateltide (IRL-1620) in a multicenter randomized controlled
clinical trial in patients with acute cerebral ischemic stroke. CNS drugs. 2021
Jan;35:85-104
9. Gulati A, Adwani
SG, Vijaya P, Agrawal NR, Ramakrishnan TC, Rai HP, Jain D, Sundarachary NV,
Pandian JD, Sardana V, Sharma M. Efficacy and Safety of Sovateltide in Patients
with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind,
Placebo-Controlled, Multicentre, Phase III Clinical Trial. Drugs. 2024
Dec;84(12):1637-50.
10. Haupt M, Gerner
ST, Bähr M, Doeppner TR. Neuroprotective strategies for ischemic stroke—future
perspectives. International journal of molecular sciences. 2023 Feb
22;24(5):4334.
11. Ranjan AK,
Gulati A. Sovateltide mediated endothelin B receptors agonism and curbing
neurological disorders. International Journal of Molecular Sciences. 2022 Mar
15;23(6):3146.
12. Berlet R,
Anthony S, Brooks B, Wang ZJ, Sadanandan N, Shear A, Cozene B,
Gonzales-Portillo B, Parsons B, Salazar FE, Lezama Toledo AR. Combination of
stem cells and rehabilitation therapies for ischemic stroke. Biomolecules. 2021
Sep 6;11(9):1316.